New regulations: After the implementation of the new "Drug Management Law", ICH, and the "Drug Management Law", what legal talents are required to understand clinical, registration and production?
New opportunities: Rare diseases, cancer drugs, cells, and gene therapy are on the rise. How can companies improve their R&D expertise?
New Ecology: After taking volume purchases and new medical insurance policies, how does the new drug research and development community formulate market access strategies in advance?
New challenge: How to balance the high cost of clinical research and development and the quality of trials under the premise of early market access intervention?